2022 AHA/ACC/HFSA 心力衰竭管理指南
AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline …
要点
- 指南基于当代证据提供心衰管理推荐,旨在提高诊疗质量并贴合患者利益。
- 文献检索涵盖MEDLINE、EMBASE、Cochrane等数据库,并补充至2021年9月的临床试验。
- 对具有高质量经济分析的治疗提供价值声明。
核心结论
- 指南基于当代证据提供心衰管理推荐,旨在改善诊疗质量并符合患者利益。
主要发现
- 心衰仍是全球发病和死亡的主要原因。
- 许多既往指南推荐已根据新证据更新,并在有发表数据支持时新增推荐。
关键数值与推荐
- 对某些具有高质量发表经济分析的治疗提供价值声明。
临床怎么用
- 临床医生应依据指南推荐对心衰患者进行预防、诊断和管理,以提供基于证据的诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. METHODS: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. STRUCTURE: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.
引用
- Heidenreich, Bozkurt, Aguilar, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022. PMID: 35379503. doi:10.1016/j.jacc.2021.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。